Atezolizumab for platinum-treated metastatic urothelial carcinoma
Mené sur 931 patients atteints d'un carcinome urothélial de stade localement avancé ou métastatique, cet essai de phase III compare l'efficacité, du point de vue de la survie globale, et la toxicité de l'atézolizumab, un anti-PD-L1, et une chimiothérapie choisie par le médecin (vinflunine, paclitaxel ou docétaxel), après l'échec d'une chimiothérapie de première ligne à base de sels de platine
In The Lancet, Thomas Powles and colleagues1 report results of the IMvigor211 study—a phase 3 randomised controlled trial assessing the safety and efficacy of atezolizumab versus chemotherapy by programmed death-ligand 1 (PD-L1) expression in 931 patients with platinum-treated metastatic urothelial carcinoma. The primary endpoint, overall survival, was tested hierarchically: first in patients with PD-L1 expression on 5% or more of the immune cells (IC2/3), then in patients with PD-L1 expression on 5% and 1% or more of the immune cells (IC1/2/3), and finally in the intention-to-treat population.
The Lancet 2017